

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



創美·CH'MEI

**CHARMACY PHARMACEUTICAL CO., LTD.**

**創美藥業股份有限公司**

*(A joint stock limited liability company established in the People's Republic of China)*

**(Stock Code: 2289)**

**ANNOUNCEMENT**

**GRANT OF EXTENSION OF WAIVER FROM STRICT COMPLIANCE**

**WITH RULE 8.08(1)(A) OF THE LISTING RULES**

References are made to (i) composite offer and response documents of the Company dated 20 January 2023 (the “**Composite Document**”); (ii) the announcement jointly issued by Jiangzhong Yishang, the offeror and the Company dated 16 February 2023 in respect of, among other things, the results and settlement of the Offer (the “**Results of Offer Announcement**”); (iii) the announcement issued by the Company in respect of the granting of waiver dated 1 March 2023 (the “**Grant of Waiver Announcement**”); and (iv) the announcement issued by the Company in respect of the update on the status of public float and application for extension of waiver dated 9 June 2023 (the “**Application for Extension of Waiver Announcement**”). Unless the context requires otherwise, capitalized terms used herein shall have the same meanings as those defined in the Composite Document, the Grant of Waiver Announcement and the Application for Extension of Waiver Announcement.

As at the date of this announcement, 23,343,500 Shares, representing approximately 21.62% of the issued share capital of the Company, are held by the public (as defined in the Listing Rules). Accordingly, the minimum public float requirement of 25% as set out in Rule 8.08(1)(a) of the Listing Rules remains unsatisfied.

As disclosed in the Application for Extension of Waiver Announcement, the temporary waiver granted by the Stock Exchange from strict compliance with Rule 8.08(1)(a) of the Listing Rules to the Company has expired on 10 June 2023. An application has been made by the Company to the Stock Exchange for an extension of the waiver from strict compliance with Rule 8.08(1)(a) of the Listing Rules from 11 June 2023 to 31 August 2023 (the “**Extension of Waiver**”).

On 14 June 2023, the Stock Exchange granted the Extension of Waiver subject to the disclosure of the waiver by way of this announcement.

The Company has been informed by the Offeror that so long as the situation allows and as soon as practicable, it will at its best efforts facilitates discussions with prospective investors with a view of placing down sufficient Shares in order to comply with the minimum public float requirement under Rule 8.08(1)(a) of the Listing Rules.

Further announcement(s) will be made by the Company regarding the restoration of the public float as and when appropriate.

By Order of the Board  
**Charmacy Pharmaceutical Co., Ltd.**  
**Yan Jingbin**  
*Chairman*

Shantou, the PRC, 14 June 2023

*As at the date of this announcement, the executive directors of the Company are Mr. Yao Chuanglong, Ms. Zheng Yuyan and Ms. Zhang Hanzi; the non-executive directors of the Company are Mr. Yan Jingbin, Ms. Fu Zheng and Mr. Xu Fei; and the independent non-executive directors of the Company are Mr. Wan Chi Wai Anthony, Mr. Li Hanguo and Mr. Guan Jian (also known as Guan Suzhe).*